Comparison of low dose oral conjugated estrogen with cryoprecipitate in prevention of bleeding among patients with acute renal failure who underwent kidney biopsy

Document Type : Original Article


1 Chronic Renal Failure Research Center, Department of Nephrology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Clinical supervisor, Ferideh Behbehani Hospital, Behbehan Faculty of Medical Sciences, Behbehan, Iran.


Background and Objective: Bleeding tendency is a complication among patients with renal failure. Many studies show the benefit effect of high dose of conjugated estrogen infusion in prevention of bleeding among uremic patients. The objective of this study was to evaluate the effect low dose orally administered conjugated estrogen in patients with acute renal failure who underwent kidney biopsy
Subjects and Methods: In this cross-sectional study, the patients were divided in two groups. In group 1, ten units of cryoprecipitate was infused on the day of biopsy and in group 2, 0.06 mg/kg conjugated estrogen in three oral divided dose was administered for 5 days before biopsy.
Results: Overall 36 patients, group 1 (9 males and 9 females) with mean age of 39.7 ±1.42 and group 2 (12 males and 6 females) with a mean age of 35.3 ± 1.13 were investigated. No significant differences between these groups in terms of mean age (P= 0.172) and males and females (P=0.310).
In both groups, hematuria was the most common complication, 15 (83.3%) in group 1 and 13 (72.2%) in group 2 with no significant differences between them (P=0.691). In group 1, two patients (11.1%) and in group 2, one patient (5.6%) had major bleeding (P=0.990). Major bleeding with hemodynamic instability occured in one case in both groups but they did not need surgical intervention.
Conclusion: According to the study, oral low dose conjugated estrogens can prevent bleeding among patient with acute renal failure who underwent kidney biopsy.


1-Sinasi S. Uremic bleeding: pathophysiology, diagnosis, and management. Hospital Physician 2001;76:45– 50.
2-Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial 2009;22(3):279-86.
3-Gawaz MP, Dobos G, Späth M, Schollmeyer P, Gurland HJ, Mujais SK. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994;5(1):36–46.
4-Pawlak D, Malyszko J, Malyszko JS, Pawlak K, Buczko W, Mysliwiec M. Peripheral serotonergic system in uremia. Thromb Res 1996;83(2):189–94.
5-Di Minno G, Cerbone A, Usberti M, Cianciaruso B, Cortese A, Farace MJ, et al. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 1986;108(3):246–52.
6-Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007;3(3):138-53.
7-Noris M, Remuzzi G. Uremic bleeding:closing the circle after 30 years of controversies? Blood 1999;94(8):2569–74.
8-Livio M, Mannucci PM, Viganò G, Mingardi G, Lombardi R, Mecca G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986;315(12):731-5.
9-Heunisch C, Resnick DJ, Vitello JM, Martin SJ. Conjugated estrogens for the management of gastrointestinal bleeding secondary to uremia of acute renal failure. Pharmacotherapy 1998;18(1):210-7.
10-Manno C, Strippoli GF, Arnesano L, Bonifati C, Campobasso N, Gesualdo L, Schena FP. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 2004;66(4): 1570-7.
11-Shemin D, Elnour M, Amarantes B, Abuelo JG, Chazan JA. Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure. Am J Med 1990;89(4):436-40.
12-Viganò G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int 1988;34(6):853-8.
13-Liu YK, Kosfeld RE, Marcum SG. Treatment of uraemic bleeding with conjugated oestrogen. Lancet 1984;324:887–90.
14-Krishnan M. Preoperative care of patients with kidney disease. Am Fam Physician 2002;66(8):1471-6.
15-Heistinger M, Stockenhuber F, Schneider B, Pabinger I, Brenner B, Wagner B, et al. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int 1990;38(6):1181-6.
16-Bronner MH, Pate MB, Cunningham JT, Marsh WH.Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure.An uncontrolled trial. Ann Intern Med 1986;105(3):371-4.
17-Zoja C, Viganò G, Bergamelli A, Benigni A, de Gaetano G, Remuzzi G. Prolonged bleeding time and increased vascular prostacyclin in rats with chronic renal failure: effects of conjugated estrogens. J Lab Clin Med 1988;112(3):380-6.
18-Soares SM, Fervenza FC, Lager DJ, Gertz MA, Cosio FG, Leung N. Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients. Am J Kidney Dis 2008;52(6):1079-83.